Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RVD With or Without ASCT in the Initial Management of Multiple Myeloma
NCT01191060Phase 3Completed
- Sponsor
- Centre hospitalier universitaire de Toulouse
- Start
- Oct 2010
- Primary completion
- Nov 2018
- Modality
- Modified Peptides, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of lenalidomide, bortezomib and dexamethasone in multiple myeloma (MM) (2 arms), sponsored by Centre hospitalier universitaire de Toulouse. Primary endpoint: Progression Free Survival up to 4 years. Started Oct 2010; status: completed.
02
Drugs
lenalidomidebortezomibdexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01191060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01191060.